A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
NCT #
NCT03425279
Condition(s)
Sarcoma
Molecular Target(s)
AXL
Drug Classification(s)
conditionally active biologic (CAB) anti-AXL humanized monoclonal antibody
Agents(s)
BA3011 (mecbotamab vedotin) and Nivolumab
Phase(s)
II
Mechanism of Action
BA3011, an anti-AXL antibody, is designed to have pH-sensitive binding to restrict its activity to the typically acidic tumor microenvironment. The Antibody target is AXL, a transmembrane that may be overexpressed in Non-Small Cell Lung Cancer.
Purpose
- About the safety and tolerability of the study agent alone or in combination with Nivolumab
- How the study agent works with and without Nivolumab in fighting cancer cells (particularly in participants with sarcomas)
- How proteins that indicate the status of your disease are affected with the use of the study agent
- How much of the study agent is absorbed into the blood and how fast it is removed
- If your body develops proteins that work against the study agent
- If research tests can be used in the future to predict who will benefit from BA3011
- If the study agent alone or in combination with Nivolumab prevents or delays tumor growth
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.